All Stories

  1. Genetic regulation of platelet-derived BDNF by rs11030119: discrepancy between circulating levels and hemostatic function
  2. The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk
  3. Consensus on Aggregometry for platelet function testing in thrombocytopenic patients: Communication from the SSC of the ISTH
  4. Biomarkers of in vivo platelet activation in coronary artery disease: a systematic review and meta-analysis: communication from the SSC of the ISTH
  5. International opinion survey on nomenclature for platelet-type von Willebrand disease: communication from the SSC of the ISTH
  6. Early vs Delayed Bypass Surgery in Patients With Acute Coronary Syndrome Receiving Ticagrelor
  7. Can the Present Canadian Health Care System Provide Evidence-Based Pharmaceutical Care? Consideration of Two Important Cardiovascular Clinical Contexts
  8. Factor XIII-A Transglutaminase Contributes to Neutrophil Extracellular Trap (NET)-mediated Fibrin(ogen) Network Formation and Crosslinking
  9. Prospective, international, multisite comparison of platelet isolation techniques for genome-wide transcriptomics: communication from the SSC of the ISTH
  10. Standardization of definition and management for bleeding disorder of unknown cause: communication from the SSC of the ISTH
  11. Effect of Heat Exposure on Inflammation and Platelet Activity in Adults with Heart Disease
  12. The intriguing role of platelets as custodians of brain-derived neurotrophic factor
  13. Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology 2023 Focused Update of the Guidelines for the Use of Antiplatelet Therapy
  14. Association of laboratory test results with the bleeding history in patients with inherited platelet function disorders (the Bleeding Assesment Tool - LABoratory tests substudy): communication from the Platelet Physiology ISTH-SSC
  15. Megakaryocytes possess a STING pathway that is transferred to platelets to potentiate activation
  16. Alpha-2-macroglobulin prevents platelet aggregation induced by brain-derived neurotrophic factor
  17. Multicenter evaluation of light transmission platelet aggregation reagents: communication from the ISTH SSC Subcommittee on Platelet Physiology
  18. Consensus report on markers to distinguish procoagulant platelets from apoptotic platelets: communication from the Scientific and Standardization Committee of the ISTH
  19. Soluble p75 neurotrophic receptor as a reliable biomarker in neurodegenerative diseases: what is the evidence?
  20. Consensus report on flow cytometry for platelet function testing in thrombocytopenic patients: communication from the SSC of the ISTH
  21. Illustrated State-of-the-Art Capsules of the ISTH 2023 Congress
  22. Assessment of Platelet Function by High-Throughput Screening Light Transmission Aggregometry: Optimul Assay
  23. Plasminogen Activator Inhibitor-1–Positive Platelet-Derived Extracellular Vesicles Predicts MACE and the Proinflammatory SMC Phenotype
  24. Expert opinion on the use of platelet secretion assay for the diagnosis of inherited platelet function disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology
  25. Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines
  26. Assessing cardiometabolic parameter monitoring in inpatients taking a second-generation antipsychotic: The CAMI-SGA study – a cross-sectional study
  27. Aspirin for Primary Cardiovascular Prevention in Patients with Diabetes: Uncertainties and Opportunities
  28. Clinical Correlates Identify ProBDNF and Thrombo-Inflammatory Markers as Key Predictors of Circulating p75NTR Extracellular Domain Levels in Older Adults
  29. Rare missense variants in Tropomyosin‐4 (TPM4) are associated with platelet dysfunction, cytoskeletal defects, and excessive bleeding
  30. Editorial: Established and Novel Roles of Platelets in Health and Disease
  31. Antiplatelet Therapy for Atherothrombotic Disease in 2022—From Population to Patient-Centered Approaches
  32. A randomized double-blind feasibility study comparing cetirizine and diphenhydramine in the prevention of paclitaxel-associated infusion-related reactions: the PREMED-F1 study
  33. Current and Novel Antiplatelet Therapies for the Treatment of Cardiovascular Diseases
  34. Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology
  35. Differences in platelet‐rich plasma composition influence bone healing
  36. The brain-derived neurotrophic factor prompts platelet aggregation and secretion
  37. Brain-Derived Neurotrophic Factor Mitigates the Association Between Platelet Dysfunction and Cognitive Impairment
  38. Effect of Paper Versus Digital Reading in Health Professional Education: A Systematic Review and Meta-Analysis
  39. The effect of aging on the bone healing properties of blood plasma
  40. Differential modulation of polyunsaturated fatty acids in patients with myocardial infarction treated with ticagrelor or clopidogrel
  41. A randomized double-blind pilot study comparing cetirizine with diphenhydramine in the prevention of paclitaxel-associated infusion-related reactions.
  42. The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology
  43. Dual antiplatelet therapy (PEGASUS) vs. dual pathway (COMPASS): a head-to-head in vitro comparison
  44. Platelet Function in Viral Immunity and SARS-CoV-2 Infection
  45. Platelet Quiescence in Patients With Acute Coronary Syndrome Undergoing Coronary Artery Bypass Graft Surgery
  46. Tissue-Specificity of Antibodies Raised Against TrkB and p75NTR Receptors; Implications for Platelets as Models of Neurodegenerative Diseases
  47. Severity of Megakaryocyte‐Driven Osteosclerosis in Mpig6b ‐Deficient Mice Is Sex‐Linked
  48. Acetylcholinesterase inhibitors and risk of bleeding and acute ischemic events in non‐hypertensive Alzheimer's patients
  49. Implications of the Antiplatelet Therapy Gap Left with Discontinuation of Prasugrel in Canada
  50. Platelets Selectively Regulate the Release of BDNF, But Not That of Its Precursor Protein, proBDNF
  51. Postoperative Administration of the Acetylcholinesterase Inhibitor, Donepezil, Interferes with Bone Healing and Implant Osseointegration in a Rat Model
  52. Advances in Platelet Function Testing—Light Transmission Aggregometry and Beyond
  53. Platelet count and disease – editorial policy
  54. Effects of reading media on reading comprehension in health professional education
  55. Differential correlation of serum BDNF and microRNA content in rats with rapid or late onset of heavy alcohol use
  56. Head-to-Head Comparison of Consensus-Recommended Platelet Function Tests to Assess P2Y12 Inhibition—Insights for Multi-Center Trials
  57. Differential Correlation of Serum BDNF and microRNA Content in Rats with Rapid or Late Onset of Heavy Alcohol Use
  58. Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC
  59. A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease
  60. Platelet Function in Aging
  61. Study of the bioaccumulation of tinzaparin in renally impaired patients when given at prophylactic doses - The STRIP study
  62. Clinical Tests of Platelet Function
  63. 750
  64. Increased platelet reactivity and platelet–leukocyte aggregation after elective coronary bypass surgery
  65. An interview with Professor Gus Born
  66. Clinical importance of thrombocytopenia in patients with acute coronary syndromes: a systematic review and meta-analysis
  67. 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy
  68. Platelets at the heart of therapy
  69. Ischemic and bleeding outcomes after coronary artery bypass grafting among patients initially treated with a P2Y12 receptor antagonist for acute coronary syndromes: Insights on timing of discontinuation of ticagrelor and clopidogrel prior to surgery
  70. Personalizing antiplatelet therapies: What have we learned from recent trials?
  71. Tailored antiplatelet therapy in high-risk ACS patients treated with PCI stenting: lessons from the ANTARCTIC trial
  72. Mice Lacking the Inhibitory Collagen Receptor LAIR-1 Exhibit a Mild Thrombocytosis and Hyperactive PlateletsHighlights
  73. PREVALENCE AND CLINICAL IMPACT OF THROMBOCYTOPENIA IN PATIENTS WITH ACUTE CORONARY SYNDROMES: A SYSTEMATIC REVIEW AND META-ANALYSIS
  74. Platelet function one and three months after coronary bypass surgery in relation to once or twice daily dosing of acetylsalicylic acid
  75. Platelet Function Tests
  76. Tests of Platelet Function
  77. ISCHEMIC AND BLEEDING OUTCOMES AFTER CORONARY ARTERY BYPASS GRAFTING AMONG PATIENTS INITIALLY TREATED WITH A P2Y12 RECEPTOR ANTAGONIST FOR ACUTE CORONARY SYNDROMES - INSIGHTS ON THE USE OF TICAGRELOR VERSUS CLOPIDOGREL PRIOR TO SURGERY
  78. ISCHEMIC AND BLEEDING OUTCOMES AFTER CORONARY ARTERY BYPASS GRAFTING AMONG PATIENTS INITIALLY TREATED WITH A P2Y12 RECEPTOR ANTAGONIST FOR ACUTE CORONARY SYNDROMES - INSIGHTS ON TIMING OF DISCONTINUATION OF TICAGRELOR AND CLOPIDOGREL PRIOR TO SURGERY
  79. The Effects of Different Aspirin Dosing Frequencies and the Timing of Aspirin Intake in Primary and Secondary Prevention of Cardiovascular Disease: A Systematic Review
  80. Platelet function testing as a biomarker for efficacy of antiplatelet drugs
  81. Whole exome sequencing identifies genetic variants in inherited thrombocytopenia with secondary qualitative function defects
  82. Platelet function tests
  83. Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation
  84. Is platelet transfusion the solution to reverse platelet inhibition in patients on triple antiplatelet therapy?
  85. SLFN14 mutations underlie thrombocytopenia with excessive bleeding and platelet secretion defects
  86. The role of platelets in the recruitment of leukocytes during vascular disease
  87. Investigating the effectiveness of different aspirin dosing regimens and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease: protocol for a systematic review
  88. Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and non-cardiac surgery: A systematic review and meta-analysis
  89. The prognostic utility of tests of platelet function for the detection of ‘aspirin resistance’ in patients with established cardiovascular or cerebrovascular disease: a systematic review and economic evaluation
  90. Use of next‐generation sequencing and candidate gene analysis to identify underlying defects in patients with inherited platelet function disorders
  91. Diversity and impact of rare variants in genes encoding the platelet G protein-coupled receptors
  92. Methodological issues and recommendations for systematic reviews of prognostic studies: an example from cardiovascular disease
  93. Evidence of platelet sensitization to ADP following discontinuation of clopidogrel therapy in patients with stable coronary artery disease
  94. A novel mutation in the P2Y12 receptor and a function‐reducing polymorphism in protease‐activated receptor 1 in a patient with chronic bleeding
  95. Evaluation of a whole blood remote platelet function test for the diagnosis of mild bleeding disorders
  96. Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assay
  97. A novel thromboxane A2 receptor N42S variant results in reduced surface expression and platelet dysfunction
  98. Enrichment of FLI1 and RUNX1 mutations in families with excessive bleeding and platelet dense granule secretion defects
  99. Utility of the ISTH bleeding assessment tool in predicting platelet defects in participants with suspected inherited platelet function disorders
  100. Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists
  101. Corrigendum
  102. Genotyping and phenotyping of platelet function disorders
  103. Testing Platelet Function
  104. Simultaneous measurement of ATP release and LTA does not potentiate platelet aggregation to epinephrine
  105. Microsatellite markers as a rapid approach for autozygosity mapping in Hermansky-Pudlak syndrome: Identification of the second HPS7 mutation in a patient presenting late in life
  106. OC-13 Investigation of underlying platelet function defects in patients with unexplained menorrhagia
  107. Protocol for a systematic review of the diagnostic and prognostic utility of tests currently available for the detection of aspirin resistance in patients with established cardiovascular or cerebrovascular disease
  108. Clinical Tests of Platelet Function
  109. G6f-Like Is an ITAM-Containing Collagen Receptor in Thrombocytes
  110. Platelet Turnover in Atherothrombotic Disease
  111. Evaluation of participants with suspected heritable platelet function disorders including recommendation and validation of a streamlined agonist panel
  112. Advances in monitoring of aspirin therapy
  113. Aspirin twice a day keeps new COX-1 at bay
  114. 50th anniversary of the discovery of ibuprofen: an interview with Dr Stewart Adams
  115. Genetic determinants of response to aspirin: Appraisal of 4 candidate genes
  116. Heterogeneity in platelet cyclooxygenase inhibition by aspirin in coronary artery disease
  117. Beware of being caught on the rebound
  118. Why an aspirin a day no longer keeps the doctor away …
  119. Platelet count, not oxidative stress, may contribute to inadequate platelet inhibition by aspirin
  120. Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel
  121. Prevalence of Unresponsiveness to Aspirin and/or Clopidogrel in Patients With Stable Coronary Heart Disease
  122. Evaluation of the platelet count drop method for assessment of platelet function in comparison with “gold standard” light transmission aggregometry
  123. Week-Long High-Maintenance Dose Clopidogrel Regimen Achieves Better Platelet Aggregation Inhibition than a Standard Loading Dose before Percutaneous Coronary Intervention: Results of a Double-Blind, Randomized Clinical Trial
  124. Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: A look at the clinical and pharmacological evidence
  125. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B2
  126. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients
  127. Assessment of VerifyNow P2Y12 Assay Accuracy in Evaluating Clopidogrel-Induced Platelet Inhibition
  128. Comparison of different methods of measurement of aspirin resistance: using the appropriate statistic: reply
  129. Normal Response to Aspirin in Healthy Individuals: Cross-Comparison of Light Transmission Aggregometry, VerifyNow™ System, Platelet Count Drop, Thrombelastography (TEG®) and Urinary 11-dehydrothromboxane B2.
  130. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease
  131. Aspirin resistance: Truth or dare